Shijiazhuang Discovery Medicine Technology Co. Ltd. has divulged compounds reported to be useful for the treatment of influenza.

Emory University has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Humanwell Healthcare (Group) Co. Ltd. has synthesized transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.

Nanjing China-Australia Institute of Translational Medicine Co. Ltd. has disclosed baculoviral IAP repeat-containing protein 3 (BIRC3; IAP1; cIAP2), baculoviral IAP repeat-containing protein 2 (BIRC2; IAP2; cIAP1) and E3 ubiquitin-protein ligase XIAP (XIAP; BIRC4; IAP3) inhibitors reported to be useful for the treatment of cancer.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described serine/threonine-protein kinase ULK1 inhibitors reported to be useful for the treatment of cancer.

Scientists at Korea Research Institute of Chemical Technology and Oncord Bio Inc. have divulged molecular glue degraders targeting protein cereblon (CRBN) and acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer, graft-vs.-host disease, leprosy and inflammatory disorders.

Nikang Therapeutics Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 2 (CDK2) targeting moiety through a linker reported to be useful for the treatment of cancer.

Ribometrix Inc. has synthesized eukaryotic translation initiation factor 4E (eiF4E) inhibitors reported to be useful for the treatment of cancer, fibrosis, inflammatory disorders and allergy.

Scientists at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and The Xinjiang Technical Institute of Physics & Chemistry of the Chinese Academy of Sciences have disclosed NMDA receptor antagonists reported to be useful for the treatment of neurological disorders.

Hangzhou Glubio Therapeutics Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase protein-binding moiety covalently linked to a Wee1-like protein kinase (Wee1)-binding moiety reported to be useful for the treatment of cancer.